For the past 15 years tamoxifen has been the standard adjuvant hormone therapy for women with early-stage breast cancer and estrogen receptor (ER)-positive tumors, irrespective of nodal status and other clinicopathological parameters. Recent studies provided evidence that the optimal duration of tamoxifen treatment is 5 years. Based on the positive clinical results obtained with the administration of aromatase inhibitors (AIs) in the metastatic setting, several controlled clinical trials have evaluated the efficacy and side effects of AIs versus standard tamoxifen also as adjuvant therapy in postmenopausal breast cancer patients. The results of the above studies, suggest a therapeutic advantage of AIs over tamoxifen with regard to relapse-free survival and the risk of metachronous contralateral breast cancer.
We review the rationale and the available clinical data on initial or sequential hormone treatment with AIs and we propose a novel scenario for possible therapeutic strategies based on the clinicopathological characteristics of the patients and on the biology of each single tumor.
IngleJ.N., SumanV.J.Aromatase inhibitors for therapy of advanced breast cancer.J Steroid Biochem Mol Biol2005; 95: 113–9.
2.
IngleJ.N.Adjuvant endocrine therapy for postmenopausal women with early breast cancer.Clin Cancer Res2006; 12(3 Suppl): 1031S–6S.
3.
ATAC Trialists' Group.Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer.Lancet2005; 365: 60–2.
4.
NicholsonR.I., HutchesonI.R., KnowldenJ.M.Nonendocrine pathways and endocrine resistance: observations with antiestrogens and signal transduction inhibitors in combination.Clin Cancer Res2004; 10: 346–54S.
5.
CuiX., SchiffR., ArpinoG., OsborneC.K., LeeA.V.Biology of progesterone receptor loss in breast cancer and its implications for endocrine therapy.J Clin Oncol2005; 23: 7721–35.
6.
BeatoM.Gene regulation by steroid hormones.Cell1989; 56: 335–44.
SchiffR., MassarwehS.A., ShouJ., BharwaniL., MohsinS.K., OsborneC.K.Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance.Clin Cancer Res2004; 10: 331S–6S.
9.
WuR.C., QinJ., HashimotoY.Regulation of SRC-3 (pCIP/ACTR/AIB-1/RAC-3/TRAM-1) coactivator activity by I kappa B kinase.Mol Cell Biol2002; 22: 3549–61.
10.
WuR.C., QinJ., YiP.Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic responses to multiple cellular signaling pathways.Mol Cell2004; 15: 937–49.
11.
Font de MoraJ., BrownM.AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor.Mol Cell Biol2000; 20: 5041–7.
12.
LavinskyR.M., JepsenK., HeinzelT.Diverse signaling pathways modulate nuclear receptor recruitment of N-CoR and SMRT complexes.Proc Natl Acad Sci U S A1998; 95: 2920–5.
13.
LevinE.R.Cellular functions of the plasma membrane estrogen receptor.Trends Endocrinol Metab1999; 10: 374–7.
14.
StewartA.J., JohnsonM.D., MayF.E.Role of insulin-like growth factors and the type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells.J Biol Chem1990; 265: 21172–8.
15.
LeeA.V., JacksonJ.G., GoochJ.L.Enhancement of insulin-like growth factor signaling in human breast cancer: Estrogen regulation of insulin receptor substrate-1 expression in vitro and in vivo.Mol Endocrinol1999; 13: 787–96.
16.
KahlertS., NuedlingS., van EickelsM.Estrogen receptor alpha rapidly activates the IGF-1 receptor pathway.J Biol Chem2000; 275: 18447–53.
17.
SimonciniT., Hafezi-MoghadamA., BrazilD.P.Interaction of oestrogen receptor with the regulatory subunit of phosphatidylinositol-3-OH kinase.Nature2000; 407: 538–41.
18.
SongR.X., McPhersonR.A., AdamL.Linkage of rapid estrogen action to MAPK activation by ERalpha-Shc association and Shc pathway activation.Mol Endocrinol2002; 16: 116–27.
19.
RazandiM., AltonG., PedramA.Identification of a structural determinant necessary for the localization and function of estrogen receptor alpha at the plasma membrane.Mol Cell Biol2003; 23: 1633–46.
20.
ShouJ., MassarwehS., OsborneC.K.Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer.J Natl Cancer Inst2004; 96: 926–35.
21.
WangR.A., MazumdarA., VadlamudiR.K., KumarR.P21-activated kinase-1 phosphorylates and transactivates estrogen receptor-? and promotes hyperplasia in mammary epithelium.EMBO J2002; 21: 5437–47.
22.
BalasenthilS., SahinA.A., BarnesC.J.p21-activated kinase-1 signaling mediates cyclin D1 expression in mammary epithelial and cancer cells.J Biol Chem2004; 279: 1422–8.
RayalaS.K., den HollanderP., BalasenthilS., YangZ.B., BroaddusR.R., KumarR.Functional regulation of oestrogen receptor pathway by the dynein light chain 1.EMBO Rep2005; 6: 538–44.
25.
VadlamudiR.K., WangR.A., MazumdarA.Molecular cloning and characterization of PELP1, a novel human coregulator of estrogen receptor?.J Biol Chem2001; 276: 38272–9.
26.
WongC.W., McNallyC., NickbargE., KommB.S., CheskisB.J.Estrogen receptor-interacting protein that modulates its nongenomic activity-crosstalk with Src/Erk phosphorylation cascade.Proc Natl Acad Sci U S A2002; 99: 14783–8.
27.
VadlamudiR.K., ManavatiB., BalasenthilS., NairS., YangZ., KumarR.Functional implications of altered subcellular localization of PELP1 in breast cancer cells.Cancer Res2005; 65: 7724–32.
28.
GururajA.E., RayalaS.K., VadlamudiR.K., KumarR.Novel mechanisms of resistance to endocrine therapy: genomic and nongenomic considerations.Clin Cancer Res2006; 12(3 Suppl): 1001S–7S.
29.
BalasenthilS., VadlamudiR.K.Functional interactions between the estrogen receptor coactivator PELP1/MNAR and retinoblastoma protein.J Biol Chem2003; 278: 22119–27.
30.
KumarR., WangR.A., Bagheri-YarmandR.Emerging roles of MTA family members in human cancers.Semin Oncol2003; 30: 30–7.
31.
KumarR., WangR.A., MazumdarA.A naturally occurring MTA1 variant sequesters oestrogen receptor-alpha in the cytoplasm.Nature2002; 418: 654–7.
32.
KurokawaH., ArteagaC.L.ErbB (HER) receptors can abrogate antiestrogen action in human breast cancer by multiple signaling mechanisms.Clin Cancer Res2003; 9: 511–5S.
33.
SlamonD.J., GodolphinW., JonesL.A.Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer.Science1989; 244: 707–12.
34.
KurokawaH., ArteagaC.L.Inhibition of erbB receptor (HER) tyrosine kinases as a strategy to abrogate antiestrogen resistance in human breast cancer.Clin Cancer Res2001; 7: 4436–42S.
35.
ArteagaC.L.The epidermal growth factor receptor: from mutant oncogene in nonhuman cancers to therapeutic target in human neoplasia.J Clin Oncol2001; 19: 32–40S.
36.
ShimW.S., ConawayM., MasamuraS.Estradiol hyper-sensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo.Endocrinology2000; 141: 396–405.
37.
PolychronisA., SinnettH.D., HadjiminasD.Preoperative gefitinib versus gefitinib and anastrozole in postmenopausal patients with oestrogen-receptor positive and epidermal-growth-factor-receptor-positive primary breast cancer: a double-blind placebo-controlled phase II randomised trial.Lancet Oncol2005; 6: 383–91.
ShinI., MillerT., ArteagaC.L.ErbB receptor signaling and therapeutic resistance to aromatase inhibitors.Clin Cancer Res2006; 12: 1008s–12s.
40.
BardouV.J., ArpinoG., ElledgeR.M., OsborneC.K., ClarkG.M.Progesterone receptor status significantly improves outcome prediction over estrogen receptor status alone for adjuvant endocrine therapy in two large breast cancer databases.J Clin Oncol2003; 21: 1973–9.
41.
RavdinP.M., GreenS., DorrT.M.l. Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study.J Clin Oncol1992; 10: 1284–91.
42.
ElledgeR.M., GreenS., PughR.Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immuno-histochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group Study.Int J Cancer2000; 89: 111–7.
43.
HuangH.J., NevenP., DrijkoningenM.Association between HER-2/neu and the progesterone receptor in oestrogen-dependent breast cancer is age-related.Breast Cancer Res Treat2005; 91: 81–7.
44.
BalleineR.L., EarlM.J., GreenbergM.L., ClarkeC.L.Absence of progesterone receptor associated with secondary breast cancer in postmenopausal women.Br J Cancer1999; 79: 1564–71.
45.
HullD.F., ClarkG.M., OsborneC.K., ChamnessG.C., KnightW.A.I., McGuireW.L.Multiple estrogen receptor assays in human breast cancer.Cancer Res1983; 43: 413–6.
46.
HorwitzK.B., McGuireW.L.Estrogen control of progesteone receptor in human breast cancer.J Biol Chem1978; 253: 2223–8.
47.
BloomN.D., TobinE.H., SchreibmanB., DegensheinG.A.The role of progesterone receptors in the management of advanced breast cancer.Cancer1980; 45: 2992–7.
48.
LapidusR.G., FergusonA.T., OttavianoY.L.Methylation of estrogen and progesterone receptor gene 5′ CpG islands correlates with lack of estrogen and progesterone receptor gene expression in breast tumors.Clin Cancer Res1996; 2: 805–10.
49.
TomlinsonI.P., NicolaiH., SolomonE., BodmerW.F.The frequency and mechanism of loss of heterozygosity on chromosome 11q in breast cancer.J Pathol1996; 180: 38–43.
50.
CuiX., ZhangP., DengW.Insulin-like growth factor-I inhibits progesterone receptor expression in breast cancer cells via the phosphatidylinositol 3-kinase/Akt/mammalian target of rapamycin pathway: progesterone receptor as a potential indicator of growth factor activity in breast cancer.Mol Endocrinol2003; 17: 575–88.
51.
Torres-ArzayusM.I., De MoraJ.F., YuanJ.High tumor incidence and activation of the PI3K/AKT pathway in transgenic mice define AIB1 as an oncogene.Cancer Cell2004; 6: 263–74.
52.
HorwitzK.B., McGuireW.L., PearsonO.H., SegaloffA.Predicting response to endocrine therapy in human breast cancer.Science1975; 189: 726–7.
53.
KimH.J., CuiX., HilsenbeckS.G., LeeA.V.Progesterone receptor loss correlates with human epidermal growth factor receptor 2 overexpression in estrogen receptor-positive breast cancer.Clin Cancer Res2006; 12(3 Suppl): 1013S–8S.
54.
WinerE.P., HudisC., BursteinH.J.American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor positive breast cancer: status report 2004.J Clin Oncol2005; 23: 619–29.
55.
Early Breast Cancer Trialists' Collaborative Group.Tamoxifen for early breast cancer: an overview of the randomized trials.Lancet1998; 351: 1451–67.
56.
PetoR.Five years of tamoxifene or more?J Natl Cancer Inst1996; 88: 1791–3.
57.
FernoM., StalO., BaldetorpB.Results of two or five years of adjuvant tamoxifen correlated to steroid receptor and S-phase levels: South Sweden Breast Cancer Group, and South-East Sweden Breast Cancer Group.Breast Cancer Res Treat2000; 59: 69–76.
58.
LamyP.J., PujolP., ThezenasS.Progesterone receptor quantification as a strong prognostic determinant in postmenopausal breast cancer women under tamoxifen therapy.Breast Cancer Res Treat2002; 76: 65–71.
59.
GrossG.E., ClarkG.M., ChamnessG.C., McGuireW.L.Multiple progesterone receptor assays in human breast cancer.Cancer Res1984; 44: 836–40.
60.
BoccardoF., RubagottiA., AmorosoD.Sequential tamoxifen and aminoglutethimide versus tamoxifen alone in the adjuvant treatment of postmenopausal breast cancer patients: results of an Italian cooperative study.J Clin Oncol2001; 19: 4209–15.
61.
CuzickJ., SasieniP., HowellA.Should aromatase inhibitors be used as initial adjuvant treatment or sequence after tamoxifen?.Br J Cancer2006; 94: 460–4.
62.
PungliaR.S., KuntzK.M., WinerE.P., WeeksJ.C., BursteinH.J.Optimizing adjuvant endocrine therapy in postmenopausal women with early-stage breast cancer: a decision analysis.J Clin Oncol2005; 23: 5178–7.
63.
HilsenbeckS.G., OsborneC.K.Is there a role for adjuvant tamoxifen in progesterone receptor-positive breast cancer? An in silico clinical trial.Clin Cancer Res2006; 12(3 Suppl): 1049s–55s.
64.
LonningP.E.Comparing cost/utility of giving an aromatase inhibitor as monotherapy for 5 years versus sequential administration following 2–3 or 5 years of tamoxifen as adjuvant treatment for postmenopausal breast cancer.Ann Oncol2006; 17: 217–5.
65.
FallowfieldL., CellaD., CuzickJ., FrancisS., LockerG., HowellA.Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) adjuvant breast cancer trial.J Clin Oncol2004; 22: 4261–71.
66.
DowsettM., CuzickJ., WaleC., HowellT., HoughtonJ., BaumM.Retrospective analysis of time to recurrence in the ATAC trial according to hormone receptor status: an hypothesis-generating study.J Clin Oncol2005; 23: 7512–7.
67.
The Breast International Group (BIG) 1–98 Collaborative Group.A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer.N Engl J Med2005; 353: 2747–57.
68.
CoombesR.C., HallE., GibsonL.J.A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer.N Engl J Med2004; 350: 1081–92.
69.
JakeszR., JonatW., GnantM.Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial.Lancet2005; 366: 455–62.
70.
BoccardoF., RubagottiA., PuntoniM.Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: preliminary results of the Italian Tamoxifen Anastrozole trial.J Clin Oncol2005; 23: 5138–47.
71.
GossP.E., IngleJ.N., MartinoS.A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for ealy stage breast cancer.N Engl J Med2003; 349: 1793–802.
72.
JakeszR., SamoniggH., GreilR.Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a).Proc Am Soc Clin Oncol2005; 23: 10s (abstr 527).
